SpringerLink
Log in

The role of βIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

The aim of this study is to evaluate whether class III β-tubulin (TUBB3) expression could predict progression-free survival or overall survival in relapsed non-small cell lung cancer (NSCLC) patients treated with taxene-based chemotherapy.

Methods

Immunohistochemistal staining was used to examine the expression of TUBB3 in resected lung tumor specimens obtained from 56 patients treated with platinum-based chemotherapy against recurrent tumors after curative resections. Excision repair cross-complementation group 1, breast cancer susceptibility gene 1, vascular endothelial growth factor, Ki-67, CD34, and p53 were also correlated with clinical features and outcome after treatment.

Results

Of the 56 patients enrolled in the study, 29 were treated by carboplatin plus paclitaxel as first-line treatment, and 24 patients received docetaxel monotherapy as second- or third-line treatment. A positive TUBB3 expression is closely associated with a poor response to taxane-based chemotherapy. TUBB3 expression was an independent prognostic factor for predicting poor progression-free survival after docetaxel administration. However, TUBB3 expression could not predict outcome after carboplatin plus paclitaxel treatment. The other biomarkers tested were not independent prognostic factors for predicting outcome after taxane-based chemotherapy.

Conclusion

TUBB3 expression is associated with resistance to taxane-based chemotherapy and is an independent prognostic factor for predicting poor progression-free survival after docetaxel treatment alone. TUBB3 expression may be a predictive marker for chemoresistance to docetaxel in NSCLC with postoperative recurrent disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Kawaguchi T, Takada M, Kubo A et al (2010) Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer. A comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol 5:620–630

    PubMed  Google Scholar 

  2. Kaira K, Yamamoto N (2010) Prognostic and predictive factors in resected non-small cell lung cancer. Expert Opin Med Diagn 4:1–9

    Article  Google Scholar 

  3. Jordan MA, Wilson L (2001) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253–265

    Article  Google Scholar 

  4. Kang CH, Jang BG, Kim DW et al (2010) The prognostic significance of ERCC1, XRCC1, and β III-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection. Lung Cancer 68:478–483

    Article  PubMed  Google Scholar 

  5. Seve P, Reiman T, Dumontet C (2010) The role of βIII-tubulin in predicting chemoresistance in non-small cell lung cancer. Lung Cancer 67:136–143

    Google Scholar 

  6. Azuma K, Sasada K, Kawahara A et al (2009) Expression of ERCC1 and class III β-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 64:326–333

    Article  PubMed  Google Scholar 

  7. Rosell R, Scagliotti G, Danenberg KD et al (2003) Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small cell lung cancer. Oncogene 22:3548–3552

    Article  PubMed  CAS  Google Scholar 

  8. Dumontet C, Isaac S, Souquet PJ et al (2005) Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer 92:E25–E30

    PubMed  Google Scholar 

  9. Seve P, Issac S, Tredan O et al (2005) Expression of class III β-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 11:5481–5486

    Article  PubMed  CAS  Google Scholar 

  10. Seve P, Mackey J, Issac S et al (2005) Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 4:2001–2007

    Article  PubMed  CAS  Google Scholar 

  11. Hayashi Y, Kuriyama H, Umezu H et al (2009) Class III β-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small-cell lung cancer. Intern Med 48:203–208

    Article  PubMed  Google Scholar 

  12. Volker M, Mone MJ, Kamakar P et al (2001) Sequential assembly of the nucleotide excision repair factors in vivo. Mol Cell 8:213–224

    Article  PubMed  CAS  Google Scholar 

  13. Simon GR, Sharma S, Cantor A et al (2005) ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 127:978–983

    Article  PubMed  Google Scholar 

  14. Olaussen KA, Dunant A, Fouret P et al (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983–991

    Article  PubMed  CAS  Google Scholar 

  15. Zheng Z, Chen T, Li X et al (2007) DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356:800–808

    Article  PubMed  CAS  Google Scholar 

  16. Mountain CF (1997) Revision in the International System for Staging Lung Cancer. Chest 11:1710–1717

    Article  Google Scholar 

  17. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

  18. Koh Y, Jang B, Han SW et al (2010) Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. J Thorac Oncol 5:320–325

    Article  PubMed  Google Scholar 

  19. Skov BG, Holm B, Erreboe A et al (2010) ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival. J Thorac Oncol 5:453–459

    Article  PubMed  Google Scholar 

  20. Kaira K, Endo M, Abe M et al (2010) Biologic correlation of 2-[18F]-fluoro-2-deoxy-d-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol 28:3746–3753

    Article  PubMed  CAS  Google Scholar 

  21. Kaira K, Oriuchi N, Shimizu K et al (2008) Evaluation of thoracic tumors with 18F-FMT and 18F-FDG PET-CT: a clinicopathological study. Int J Cancer 124:1152–1160

    Article  Google Scholar 

  22. Kaira K, Oriuchi N, Imai H et al (2008) Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer 98:742–748

    Article  PubMed  CAS  Google Scholar 

  23. Davies AM, Lara PN Jr, Mack PC et al (2003) Docetaxel in non-small cell lung cancer: a review. Expert Opin Pharmacother 4:553–565

    Article  PubMed  CAS  Google Scholar 

  24. Maio MD, Chiodini P, Georgoulias V et al (2009) Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 27:1836–1843

    Article  PubMed  Google Scholar 

  25. Azuma K, Komohara Y, Sasada T et al (2007) Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci 98:1336–1343

    Article  PubMed  CAS  Google Scholar 

  26. Vilmar A, Santoni-Rugiu E, Sørensen JB (2010) ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial. Eur J Cancer 13:1554–1562

    Article  Google Scholar 

  27. Sekine I, Nokihara H, Yamamoto N et al (2009) Comparative chemotherapeutic efficacy in non-small cell lung cancer patients with postoperative recurrence and stage IV disease. J Thorac Oncol 4:518–521

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported in part by Grant 21790793 (K. K) from the Ministry of Education, Culture, Sports, Science and Technology, Japan, and National Hospital Organization Policy Based Medical Services. We thank the staffs of all pathology departments in the Shizuoka Cancer Center for their technical assistance in the immunohistochemical analysis.

Conflict of interest

The authors declare that they have no financial or personal relationships with other individuals or organizations that could inappropriately influence this research.

Author information

Authors and Affiliations

  1. Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan

    Kyoichi Kaira, Toshiaki Takahashi, Haruyasu Murakami, Takehito Shukuya, Hirotsugu Kenmotsu, Akira Ono, Tateaki Naito, Asuka Tsuya, Yukiko Nakamura & Nobuyuki Yamamoto

  2. Division of Thoracic Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan

    Haruhiko Kondo

  3. Division of Diagnostic Radiology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan

    Masahiro Endo

  4. Division of Diagnostic Pathology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan

    Takashi Nakajima

Authors
  1. Kyoichi Kaira
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toshiaki Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Haruyasu Murakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takehito Shukuya
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hirotsugu Kenmotsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Akira Ono
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tateaki Naito
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Asuka Tsuya
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yukiko Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Masahiro Endo
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Haruhiko Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Takashi Nakajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Nobuyuki Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kyoichi Kaira.

About this article

Cite this article

Kaira, K., Takahashi, T., Murakami, H. et al. The role of βIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy. Int J Clin Oncol 18, 371–379 (2013). https://doi.org/10.1007/s10147-012-0386-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-012-0386-8

Keywords

Search

Navigation